Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases

Jie Zheng,Valeriia Haberland,Denis Baird,Venexia Walker,Philip C. Haycock,Mark R. Hurle,Alex Gutteridge,Pau Erola,Yi Liu,Shan Luo,Jamie Robinson,Tom G. Richardson,James R. Staley,Benjamin Elsworth,Stephen Burgess,Benjamin B. Sun,John Danesh,Heiko Runz,Joseph C. Maranville,Hannah M. Martin,James Yarmolinsky,Charles Laurin,Michael V. Holmes,Jimmy Z. Liu,Karol Estrada,Rita Santos,Linda McCarthy,Dawn Waterworth,Matthew R. Nelson,George Davey Smith,Adam S. Butterworth,Gibran Hemani,Robert A. Scott,Tom R. Gaunt

DOI: https://doi.org/10.1038/s41588-020-0682-6

IF: 30.8

2020-09-07

Nature Genetics

Abstract:The human proteome is a major source of therapeutic targets. Recent genetic association analyses of the plasma proteome enable systematic evaluation of the causal consequences of variation in plasma protein levels. Here we estimated the effects of 1,002 proteins on 225 phenotypes using two-sample Mendelian randomization (MR) and colocalization. Of 413 associations supported by evidence from MR, 130 (31.5%) were not supported by results of colocalization analyses, suggesting that genetic confounding due to linkage disequilibrium is widespread in naïve phenome-wide association studies of proteins. Combining MR and colocalization evidence in <i>cis</i>-only analyses, we identified 111 putatively causal effects between 65 proteins and 52 disease-related phenotypes (<a href="http://www.epigraphdb.org/pqtl/">https://www.epigraphdb.org/pqtl/</a>). Evaluation of data from historic drug development programs showed that target-indication pairs with MR and colocalization support were more likely to be approved, evidencing the value of this approach in identifying and prioritizing potential therapeutic targets.

genetics & heredity

What problem does this paper attempt to address?

The problem that this paper attempts to solve is how to improve the success rate of new drug development in the process of drug research and development. Specifically, the paper gives priority to target - indication pairs that are more likely to succeed by systematically evaluating genetic evidence. The study points out that although the pharmaceutical industry's investment in research and development is increasing continuously, the success rate of new drugs has been declining, resulting in an increase in the cost of new therapies and a decrease in their availability. Therefore, it is particularly important to determine early which target - indication pairs are more likely to succeed.

The paper proposes that by using the Mendelian Randomization (MR) method in combination with Genome - Wide Association Studies (GWAS) data, the causal effects of a large number of potential drug targets can be systematically tested, thus providing a basis for prioritizing drug development projects. Specifically, the researchers used genetic variations related to plasma protein levels and, through MR analysis, evaluated the causal impact of these proteins on human disease phenotypes.

Through this method, the study aims to identify protein targets with potential therapeutic value and provide a scientific basis for drug development, in order to reduce the failure rate in the drug development process and increase the success rate of new drugs.